Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) completed a record run of 1.8 metric tons of recombinant spider‑silk cocoons into finished reeled silk, the largest single inventory the company has produced to date.
The reeling operation began on April 20 2026 and is expected to finish by the end of the month. The 1.8‑metric‑ton inventory includes the 1.3‑metric‑ton run announced in March and an additional half‑ton of cocoons that were not included in the March report.
The milestone demonstrates the scalability of KBLB’s BAM‑1 Alpha platform and signals that the company is moving closer to generating revenue from its first major customer orders. By converting a record volume of cocoons into finished silk, the company is proving that its production infrastructure can support future contracts and may attract non‑dilutive financing or strategic partnerships.
However, the company remains pre‑revenue and has reported significant losses. For the full year ended December 31 2025, KBLB posted a net loss of $3.62 million, compared with a $3.4 million loss a year earlier. The quarter ended September 30 2025 saw a net loss of $1.51 million, an increase of 248.47 % from the prior year. An auditor’s going‑concern warning highlights the ongoing financial risk.
Founder and CEO Kim Thompson emphasized the progress: "We laid out an ambitious plan to scale production to unprecedented levels, and we are now systematically delivering against that roadmap." He added, "We set a plan, we delivered, and now we are moving immediately to expand on that success."
The company has no analyst coverage and has reported zero revenue in both 2024 and 2025. While the production milestone is a positive operational development, the lack of revenue and persistent losses underscore the need for continued capital and strategic partnerships to achieve commercial viability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.